Advertisements
Feeds:
Posts
Comments

Posts Tagged ‘BMC Medicine’

SAME SCIENTIFIC IMPACT: Scientific Publishing – Open Journals vs. Subscription-based


Reporters: Aviva Lev-Ari, PhD, RN & Pnina G. Abir-Am, PhD

Drastic change in academic education by design: FREE ACCESS to knowledge — Program edX – the  Harvard+MIT collaboration on Online education!! 
FREE ACCESS to Scientific Journals will be the next step. Research to support that by a study carried by Bjork, B. C., and D. Solomon. 2012. Open access versus subscription journals: a comparison of scientific impact. BMC Medicine. 10(1):73+. 
“Following step will be to demonstrated that Scientific Websites like http://pharmaceuticalintelligence.com have SAME Scientific impact as Open Journals!!
“We are well positioned to demonstrate that” said Aviva Lev-Ari, PhD, RN, Director & Founder of Leaders in Pharmaceutical Business Intelligence and the 2/2012 launcher of the initiative called  http://pharmaceuticalintelligence.com  To trace her contributions to Research Methodology, 1976-2005, go to  https://sites.google.com/site/avivasopusmagnum/aviva-s-home-page
The merit of Scientific Website is manifold:
  • Time from Lab/Desk to Publication on the Internet and Search engines is reduced to seconds
  • comments by other scientists are equally valuable to peer review
  • collaboration with other scientist around the globe is fostered on WWW
  • the platform is of collaborative authoring, we have 60 categories of research in one site
  • interdisciplinary work can be published in one site the over arching domain in our case is Life Sciences, Pharmaceutical and Healthcare
In May 2012 MIT and Harvard are collaborating on distribution of course material of all classes on the Internet – a Program called EdX
In the Press Release“EdX represents a unique opportunity to improve education on our own campuses through online learning, while simultaneously creating a bold new educational path for millions of learners worldwide,” MIT President Susan Hockfield said.

Harvard President Drew Faust said, “edX gives Harvard and MIT an unprecedented opportunity to dramatically extend our collective reach by conducting groundbreaking research into effective education and by extending online access to quality higher education.”

“Harvard and MIT will use these new technologies and the research they will make possible to lead the direction of online learning in a way that benefits our students, our peers, and people across the nation and the globe,” Faust continued.

Princeton, Stanford, Michigan and the University of Pennsylvania announced that they would offer free Web-based courses through a for-profit company called Coursera that was founded by two Stanford computer science professors. One of those professors, Andrew Ng, taught a free online course in machine learning this past fall with an enrollment of more than 100,000 students.

There’s also Udacity, co-founded by a former Stanford professor, andKhan Academy, which boasts 3,100 free educational videos across a variety of subjects.

MIT and Harvard said that they hope to eventually partner with other universities to expand the offerings on the edX platform.

Results of the BMC Medicine study are reported, below and they are:  Open Access, But Same Impact
profile

BioTechniques

http://www.biotechniques.com/news/Open-Access-But-Same-Impact/biotechniques-333012.html#.UA2SsRxueMU 

Open Access, But Same Impact

07/19/2012

Jesse Jenkins
By comparing two-year impact factors for journals, researchers found that open access and subscription-based journals have about the same scientific impact.
Open access (OA) journals are approaching the same scientific impact and quality as traditional subscription journals, according to a new study. In a study published in BMC Medicine on July 17 (1), researchers surveyed the impact factors, the average number of citations per paper published in a journal during the two preceding years, of OA and traditional subscription journals.

By comparing two-year impact factors for journals from the four countries that publish the most scientific literature, researchers have found that OA journals have about the same scientific impact as their subscription-based counterparts. Source: BMC Medicine.

At first, the study’s authors—Bo-Christer Björk from the Hanken School of Economics in Helsinki, Finland, and David Solomon from the College of Human Medicine at Michigan State University—found that there was a 30% higher average citation rate for subscription journals. But after controlling for journal discipline, location of publisher, and age of publication, their results showed that OA and subscription journals had nearly identical scientific impact.

“The newer open access published within the last 10 years, particularly those journals funded by article processing fees, had basically the same impact as subscription journals within the same category,” said Solomon. “I think that that is the key finding.”

The initial higher citation rate for subscription journals was the result of a higher percentage of older OA journals from countries that are not major publishing countries. “A lot of them are from South America or other developing countries, and they tend to have lower impact factors,” said Solomon. “When you compare apples to apples and start looking within subgroups, particularly journals launched after 2000 in biomedicine for example, the differences fall away.”

However, the authors identified a sector of low quality, OA publishers that are looking to capitalize on the article processing charge model rather than contribute to the advancement of science. Solomon said that this could partly be to blame for negative perceptions about the integrity of OA publishing as a whole and its impact on the peer review system. But most researchers are aware of these low-quality publishers and prefer to publish in more reputable OA journals.

In the end, Bjork and Solomon are hopeful that the study’s findings may help dispel some of the misconceptions in the debate over OA publishing. “Open access journals still have the reputation of being second class in the minds of some people. So, we think that this is important because this is objective data verifying that at least the open access journals published in the last 10 years by professional publishers are on par with subscription journals.”

References

  1. Bjork, B. C., and D. Solomon. 2012. Open access versus subscription journals: a comparison of scientific impact. BMC Medicine. 10(1):73+.
Advertisements

Read Full Post »


Reporter: Prabodh Kandala, PhD

You know that vegetables are good for you. And cruciferous vegetables – broccoli, cabbage, cauliflower, brusselsprouts – are especially healthful. New studies are demonstrating the anti-cancer effects of an ingredient in these green goddesses.

Diindolylmethane (DIM) is the wonder ingredient found in cruciferousvegetables. DIM is also sold over-the-counter as a supplement.

Researchers have found that DIM kills ovarian cancer cells in the laboratory and also improves the effectiveness of a commonly used chemotherapy agent.

Prabodh K. Kandala and Sanjay K. Srivastava, researchers in the Department of Biomedical Sciences and Cancer Biology Center at Texas Tech University Health Sciences Center, made the discoveries.

Researchers already knew that DIM slows the growth of ovarian cancer cells. In a detailed look at how the chemical behaves, they learned that DIM works by blocking the gene STAT3, which is seen in 90 percent of ovarian cancers.

In addition to causing cell death, DIM also prevented the cancer cells from invading or developing blood vessel structures which are key processes in cancer growth.

A platinum-based chemotherapy drug – cisplatin – is used to treat women with ovarian cancer. The drug doesn’t always work, though, and some patients become resistant to it.

For this study, researchers found that when DIM was combined withcisplatin, tumor growth in mice was slowed 50 percent more than when the chemo was used alone.

“DIM increases the effect of cisplatin, without being toxic to normal ovarian cells, by targeting STAT3 signaling and increasing apoptosis,” the authors explained.

“Cisplatin is very toxic and has severe side effects. If co-treatment with DIM means that a low dose of cisplatin can be given to patients without the loss of therapeutic effect, but with reduced side effects, it would represent a significant breakthrough in clinical practice,” Kandala andSrivastava concluded.

For the experiments, the supplement BioResponse DMI was used.

A number of clinical trials are currently under way to study the impact of DIM on a variety of malignancies including cancers of the breast, prostate, pancreas, kidney and others.

This new research was published in BioMed Central‘s open access journalBMC Medicine.

http://www.dailyrx.com/news-article/ovarian-cancer-cells-killed-dim-17180.html

http://www.ncbi.nlm.nih.gov/pubmed/22280969

 

Read Full Post »